DXCM Company Profile and Key Details

Q: Who are the executives of DXCM?

Ms. Sadie M. SternExecutive Vice President & Chief HR OfficerMr. Steven R. PacelliExecutive Vice President & MD of Dexcom VenturesMr. Jacob Steven LeachExecutive Vice President & Chief Operating OfficerMr. Sean ChristensenDirector of Corporation Affairs & Head of Investor RelationsMr. Matthew DolanExecutive Vice President of Strategy, Corporation Devel. & Dexcom LabsMr. Jereme M. SylvainExecutive Vice President, Chief Financial Officer & Chief Accounting OfficerMr. Paul R. FlynnExecutive Vice President of Global RevenueMr. Kevin Ronald SayerExecutive Chairman, Chief Executive Officer & PresMr. Andrew K. BaloExecutive Vice President of Global Medical Affairs, Access & EvidenceMr. Girish NaganathanExecutive Vice President of R&D and Chief Technology OfficerMr. Shelly Ramasamy SelvarajSenior Vice President & Chief Information OfficerMr. Michael Jon BrownExecutive Vice President & Chief Legal Officer

NASDAQ : DXCM

DexCom

$73.08

-0.7-0.95%

At Close 4:00 PM

52.7

B-ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

DexCom, Inc. (DXCM) stock declined over -0.25%, trading at $72.90 on NASDAQ, down from the previous close of $73.08. The stock opened at $73.03, fluctuating between $71.10 and $73.57 in the recent session.

Stock Snapshot

73.08

Prev. Close

28.43B

Market Cap

71.1

Day Low

34.88

P/E Ratio

2.09

EPS (TTM)

1.33

Cash Flow per Share

73.03

Open

390.02M

Number of Shares

73.57

Day High

99.33%

Free Float in %

5.39

Book Value

4.16M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 03, 2026	72.47	73.53	72.25	73.08	2.38M
Mar 02, 2026	72.37	73.91	71.57	73.78	3.63M
Feb 27, 2026	73.58	74.35	73.03	73.43	5.44M
Feb 26, 2026	73.45	74.43	72.83	74.38	2.88M
Feb 25, 2026	73.42	73.71	72.34	73.16	3.22M
Feb 24, 2026	73.31	73.61	70.81	73.09	4.14M
Feb 23, 2026	73.07	74.49	72.86	73.26	4.86M
Feb 20, 2026	72.35	73.37	72.04	73.08	3.32M
Feb 19, 2026	72.79	73.26	71.61	72.27	3.45M
Feb 18, 2026	70.71	73.24	70.03	72.80	4.44M
Feb 17, 2026	70.25	72.19	69.81	70.43	5.91M
Feb 13, 2026	64.44	71.34	62.86	70.02	10.81M
Feb 12, 2026	68.01	69.00	64.88	65.08	7.67M
Feb 11, 2026	68.28	68.55	67.04	68.15	5.17M
Feb 10, 2026	70.18	70.34	68.13	68.16	7.88M
Feb 09, 2026	69.01	70.21	67.87	70.16	4.03M
Feb 06, 2026	70.57	70.68	68.68	69.97	3.66M
Feb 05, 2026	70.98	72.06	69.63	69.89	5.56M
Feb 04, 2026	71.86	72.26	70.51	70.82	7.05M
Feb 03, 2026	72.55	75.36	70.73	71.63	5.02M

Contact Details

San Diego, CA 92121

United States

https://www.dexcom.com 858 200 0200

About Company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.

Stock Peers

SWAV

-0.08-0.02%

ShockWave Medical, Inc.$334.75 BRKRP

-13.82-4.43%

Bruker Corporation 6.375% Mandatory Convertible Preferred Stock, Series A$298.37 PODD

-3.61-1.47%

Insulet Corporation$241.84 UFPT

-1.39-0.68%

UFP Technologies, Inc.$202.91 ALGN

-6.38-3.38%

Align Technology, Inc.$182.64 TMDX

1+0.68%

TransMedics Group, Inc.$148.00 IRTC

-2.61-2.03%

iRhythm Technologies, Inc.$125.85 IRMD

0.55+0.53%

IRadimed Corporation$104.29 NARI

Inari Medical, Inc.$79.97 ESTA

-4.985-6.55%

Establishment Labs Holdings Inc.$71.11

Company Overview

DexCom, Inc. (NASDAQ:DXCM) closed at $72.90 USD, losing -$0.18 (-0.25%) from the previous close of $73.08. The stock is currently mid-range between its 52-week high and low $54.11 and $89.98. With a market capitalization of about $28.43 billion, DexCom, Inc. is classified as a large-cap and shows higher-than-market volatility (beta ~1.53). Key stats such as the average daily volume over the past year has been around 5.25 million shares, in line with its 52-week average. Headquartered in San Diego, CA, DexCom, Inc. operates in the Healthcare sector and the Medical - Devices industry. Led by CEO Jacob Steven Leach, the company employs approximately 10,200 people and listed since April 14, 2005. DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally.

Technical Performance

Short-term trend indicators are mixed aligned (SMA20 4.33%, SMA50 6.39%, SMA200 0.64%). The stock’s 14-day RSI is 62.27 (firm momentum), while the ATR of 2.41 points to higher daily volatility. The stock remains sitting in the mid-range of its 52-week band, trading -17.96% below its high and over 37.46% above its low. Average 10-day trading volume of 3.79 million shares is below the 3-month average of 5.17 million, indicating normal recent market interest.

Valuation Metrics

DexCom, Inc. trades at a P/E ratio of 33.7, slightly above the S&P 500 average, with a price-to-sales ratio of 6.1 and a price-to-book ratio of 10.26 reflecting a rich premium to book value. The P/FCF stands at 26.39, also below market averages. Compared to sector medians, DexCom, Inc. P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

DexCom, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $74.49. This means the shares are trading near this model’s fair value.

Earnings & Analyst Outlook

DexCom, Inc. generated EPS of $2.09 over the past year. Five-year average earnings growth is 10.55%. Wall Street analysts project EPS growth of 19.65% annually over the next five years. The latest quarter delivered EPS of $0.61. The next quarter is forecast at $0.47. Next year's EPS is expected at $19.82. Analyst sentiment is bullish. Analyst rating data shows there are 14 Strong Buy ratings, 24 Buy ratings, 6 Hold ratings, 0 Sell rating and 2 Strong Sell ratings. Price targets range from $106.00 to $63.00. The high target offers 45.05% upside. The low target suggests -13.79% downside. The mean target is $88.93. This offers 21.69% upside. DexCom, Inc. earnings surprise history is a mixed track record. The quarter that ended October 30, 2025, missed forecasts by 7.02%. The prior quarter beat by 8.21%. Over the last six quarters, Apple has recorded several small beats. These include 11.34% in July 25, 2024.

Shareholding & Insider Activity

DexCom, Inc. has 392.16 million shares outstanding. The public float is 389.52 million shares, elevated short interest at 3.63% of float. This equals 11.10 million shares. The short ratio is 2.59 days. Institutional investors hold 97.92% of the float. Insiders own 0.42%. SAYER KEVIN R holds 372.03 thousand shares, Leach Jacob Steven has 329.20 thousand shares and Pacelli Steven Robert has 124.78 thousand shares. Over the past six months, insider transactions show net selling. They sold 11.01 thousand shares across 6 transactions.

Financial & Profitability Overview

Over the trailing twelve months, DexCom generated $3.62B in revenue, or $8.51 per share. Gross margin was 63.19%, operating margin 16.50%, and net profit margin 14.95%. Returns are healthy, with ROA at 8.64% and ROE at 26.18%.
On valuation metrics, DexCom trades at a P/E of 33.70, P/S of 6.10 and P/B of 10.26. The current ratio is 1.88 and quick ratio is 1.59. Operationally, the company’s inventory turnover is 2.96 and cash conversion cycle is 156.87 days. Debt-to-equity is 0.51, supported by a cash flow-to-debt ratio of 1.04.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, DexCom posted revenue of $3.62B, down slightly from $2.91B in the prior quarter. Gross profit was $2.29B (margin 63.19%). Operating income was $597.70M (margin 16.5%). Net income was$541.50M (EPS $1.40).
The company ended the quarter with $2.72B in cash and short-term investments, a total debt of $2.59B, and net debt of $2.03B. Total assets were $6.26B, with equity of $2.07B. Financials further reflected stability, with operating cash flow of $748.50M, free cash flow of $511.90M, and capital expenditures of - $236.60M.

Price Forecast & Outlook

Our AI price prediction model suggests that DexCom, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 7.05%, with price expected at $78.23 by March 17, 2026, within a range of $75.96 to $80.32 3-Month Outlook: Projected fall of -3.01%, reaching $70.88 by June 01, 2026, with a range of $68.86 to $73.32. 1-Year Outlook: Projected loss of -26.49%, with price at $53.72 by March 03, 2027, within a range of $48.38 to $58.54.

Key Takeaways

DexCom, Inc. (NASDAQ:DXCM) shares are flat 6.57% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows DexCom, Inc. trading at a premium to the broader market with a P/E of 33.7. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $145.54, suggesting 99.15% upside. Our AI forecast model points to short-term strength (7.05% over two weeks), a medium-term fall (-3.01% over three months), and a longer-term loss (-26.49% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current DexCom, Inc. (DXCM) stock price?

DexCom, Inc. (NASDAQ: DXCM) stock price is $72.90 in the last trading session. During the trading session, DXCM stock reached the peak price of $73.57 while $71.10 was the lowest point it dropped to. The percentage change in DXCM stock occurred in the recent session was -0.25% while the dollar amount for the price change in DXCM stock was - $0.18.

DXCM's industry and sector of operation?

The NASDAQ listed DXCM is part of Medical - Devices industry that operates in the broader Healthcare sector. DexCom, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of DXCM?

Ms. Sadie M. Stern
Executive Vice President & Chief HR Officer
Mr. Steven R. Pacelli
Executive Vice President & MD of Dexcom Ventures
Mr. Jacob Steven Leach
Executive Vice President & Chief Operating Officer
Mr. Sean Christensen
Director of Corporation Affairs & Head of Investor Relations
Mr. Matthew Dolan
Executive Vice President of Strategy, Corporation Devel. & Dexcom Labs
Mr. Jereme M. Sylvain
Executive Vice President, Chief Financial Officer & Chief Accounting Officer
Mr. Paul R. Flynn
Executive Vice President of Global Revenue
Mr. Kevin Ronald Sayer
Executive Chairman, Chief Executive Officer & Pres
Mr. Andrew K. Balo
Executive Vice President of Global Medical Affairs, Access & Evidence
Mr. Girish Naganathan
Executive Vice President of R&D and Chief Technology Officer
Mr. Shelly Ramasamy Selvaraj
Senior Vice President & Chief Information Officer
Mr. Michael Jon Brown
Executive Vice President & Chief Legal Officer

How DXCM did perform over past 52-week?

DXCM's closing price is 35.06% higher than its 52-week low of $54.11 where as its distance from 52-week high of $89.98 is -18.78%.

How many employees does DXCM have?

Number of DXCM employees currently stands at 10,200.

Link for DXCM official website?

Official Website of DXCM is: https://www.dexcom.com

How do I contact DXCM?

DXCM could be contacted at phone 858 200 0200 and can also be accessed through its website. DXCM operates from 6340 Sequence Drive, San Diego, CA 92121, United States.

How many shares of DXCM are traded daily?

DXCM stock volume for the day was 4.16M shares. The average number of DXCM shares traded daily for last 3 months was 5.25M.

What is the market cap of DXCM currently?

The market value of DXCM currently stands at $28.43B with its latest stock price at $72.90 and 390.02M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	10200
Beta	1.49
Sales or Revenue	$3.62B
5Y Sales Change%	2.209%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Medical - Devices

DXCM Company Profile and Key Details

DexCom

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Shareholding & Insider Activity

Company Overview

Price Forecast & Outlook

Key Takeaways

Earnings & Analyst Outlook

Valuation Metrics